ES 285
Alternative Names: ES-285Latest Information Update: 13 Nov 2008
At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Cytoskeletal protein inhibitors; Glucosylceramide synthase inhibitors; Rho GTP-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Oct 2008 Efficacy & adverse events data from three phase I trials in Solid tumours presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
- 31 Dec 2007 Discontinued - Phase-I for Solid tumours in Spain (IV)
- 31 Dec 2007 Discontinued - Phase-I for Solid tumours in USA (IV)